SAMSUNG BIOLOGICS CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 781,000 KRW | 0.00% |
|
+1.30% | +2.76% |
| 05-06 | Samsung Group Firms Set to Invest in US-based Latus Bio | MT |
| 04-25 | Samsung Bioepis Granted Approval to Market Autoimmune Treatment in Europe | MT |
| Sales 2024 * | 4,266B 3.13B 249B | Sales 2025 * | 4,931B 3.61B 287B | Capitalization | 55,587B 40.75B 3,240B |
|---|---|---|---|---|---|
| Net income 2024 * | 975B 715M 56.83B | Net income 2025 * | 1,178B 863M 68.66B | EV / Sales 2024 * | 12.6 x |
| Net cash position 2024 * | 1,742B 1.28B 102B | Net cash position 2025 * | 2,750B 2.02B 160B | EV / Sales 2025 * | 10.7 x |
| P/E ratio 2024 * |
57
x | P/E ratio 2025 * |
48.4
x | Employees | 4,284 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 25.25% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 week | +1.30% | ||
| 1 month | -1.14% | ||
| 3 months | -6.80% | ||
| 6 months | +8.47% | ||
| Current year | +2.76% |
1 week
779 000.00
803 000.00
1 month
768 000.00805 000.00
Current year
739 000.00880 000.00
1 year
668 000.00880 000.00
3 years
668 000.001 000 000.00
5 years
241 500.001 000 000.00
10 years
125 500.001 000 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
John Chongbo Rim
CEO | Chief Executive Officer | 62 | 31/12/17 |
Doyoung Heo
DFI | Director of Finance/CFO | - | - |
Tae-Han Kim
CHM | Chairman | 66 | 20/04/11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chang-Woo Lee
BRD | Director/Board Member | 70 | - |
Tae-Han Kim
CHM | Chairman | 66 | 20/04/11 |
Seok-Woo Jung
BRD | Director/Board Member | 62 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.63% | 2 M€ | -14.14% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/05/24 | 781,000 | 0.00% | 28 248 |
| 13/05/24 | 781,000 | -0.76% | 35,239 |
| 10/05/24 | 787,000 | +0.77% | 65,984 |
| 09/05/24 | 781,000 | -1.26% | 82,989 |
| 08/05/24 | 791,000 | +0.76% | 82,414 |
End-of-day quote Korea S.E., May 13, 2024
More quotes
Samsung Biologics Co Ltd is a Korea-based company primarily engaged in development, manufacture and distribution of biological products. The Company, as a contract manufacturing organization (CMO), mainly develops and manufactures antibody drugs used for treatment of cancer, autoimmune disease, diabetes and chronic diseases. It also provides cell line development and process development services. The Company distributes its products in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
23/07/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
781,000
KRW
Average target price
1,032,833
KRW
Spread / Average Target
+32.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.76% | 40.65B | |
| -2.47% | 89.37B | |
| -12.32% | 32.81B | |
| +52.41% | 25B | |
| -17.39% | 15.29B | |
| -42.45% | 11.61B | |
| -10.48% | 11.49B | |
| +6.14% | 8.98B | |
| -7.72% | 8.23B | |
| -8.25% | 7B |
- Stock Market
- Equities
- A207940 Stock
